Cue Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview
15/03/2024 21:08
* Cue Biopharma Inc CUE.OQ CUE.O is expected to show a
rise in
quarterly revenue when it reports results on March 19
(estimated) for the period ending December 31 2023
* The Boston Massachusetts-based company is expected to
report a
937.7% increase in revenue to $1.567 million from $151 thousand
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Cue Biopharma Inc is for
a
loss of 28 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Cue
Biopharma Inc
is $8.00, above its last closing price of $2.03.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.30 -0.34 -0.24 Beat 29.9
Jun. 30 2023 -0.30 -0.30 -0.29 Beat 4.9
Mar. 31 2023 -0.32 -0.29 -0.29 Met 0
Dec. 31 2022 -0.29 -0.31 -0.38 Missed -22.6
Sep. -0.38 -0.38 -0.31 Beat 18.4
30 2022
Jun. 30 2022 -0.43 -0.42 -0.37 Beat 12.6
Mar. 31 2022 -0.43 -0.43 -0.44 Missed -2.9
Dec. 31 2021 -0.45 -0.38 -0.25 Beat 35.1
This summary was machine generated March 15 at 21:08 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)